NCT02024230

Rivaroxaban Estimation With Warfarin in Atrial Fibrillation Patients With Coronary Stent Implantation Study (REWRAPS)

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 500 (actual)
• Sponsor: Fujita Health University · Academic / Other
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

Antiplatelet therapy is indispensable for the prevention of stent thrombosis in patients who underwent coronary artery stenting. Similarly, anticoagulant therapy is essential for the prevention of cardiogenic embolism including cerebral infarction in AF patients. However, the combined antithrombotic therapy has been reported to increase the risk of major bleeding for AF patients after coronary stenting, New anticoagulant drugs that hardly interact with other drugs and do not need frequent blood tests have become commonly used. The purpose of this study is to assess the hypothesis that Rivaroxaban is non-inferior to Warfarin in the efficacy and safety for AF patients after coronary stenting

Conditions

• Coronary Artery Disease
• Atrial Fibrillation
• Stroke
• Fetal Blood Loss
• Major Bleeding
• All Cause Mortality

Interventions

Type	Name	Description
DRUG	Rivaroxaban or Warfarin	a multi-center, prospective, non-randomized, open-label, physician-initiated interventional allocation study either rivaroxaban or warfarin

Timeline

• Start date: 2014-01-01
• Primary completion: 2018-12-01
• Completion: 2022-12-01
• First posted: 2013-12-31
• Last updated: 2023-01-03

Locations

1 site across 1 country: Japan